Spero Therapeutics (NASDAQ:SPRO) Raised to “Strong-Buy” at Wall Street Zen

Spero Therapeutics (NASDAQ:SPRO) was upgraded by stock analysts at Wall Street Zen from a “hold” rating to a “strong-buy” rating in a research report issued on Sunday.

Separately, Weiss Ratings reissued a “sell (d-)” rating on shares of Spero Therapeutics in a research report on Thursday, January 22nd. One analyst has rated the stock with a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, Spero Therapeutics has a consensus rating of “Reduce”.

Spero Therapeutics Trading Down 3.9%

Shares of SPRO opened at $2.24 on Friday. The stock has a market capitalization of $129.67 million, a price-to-earnings ratio of 18.67 and a beta of 1.45. Spero Therapeutics has a 12 month low of $0.51 and a 12 month high of $3.22. The firm has a fifty day simple moving average of $2.35 and a 200 day simple moving average of $2.31.

Spero Therapeutics (NASDAQ:SPRO) last issued its quarterly earnings results on Thursday, March 26th. The company reported $0.53 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.20) by $0.73. Spero Therapeutics had a net margin of 12.83% and a return on equity of 22.53%. The firm had revenue of $41.30 million for the quarter, compared to analyst estimates of $26.00 million. As a group, research analysts predict that Spero Therapeutics will post -1.2 earnings per share for the current fiscal year.

Insider Transactions at Spero Therapeutics

In related news, insider Esther Rajavelu sold 87,917 shares of Spero Therapeutics stock in a transaction dated Friday, February 6th. The stock was sold at an average price of $2.36, for a total transaction of $207,484.12. Following the completion of the transaction, the insider owned 1,012,091 shares in the company, valued at approximately $2,388,534.76. This trade represents a 7.99% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Company insiders own 5.50% of the company’s stock.

Institutional Trading of Spero Therapeutics

A number of hedge funds have recently made changes to their positions in SPRO. XTX Topco Ltd acquired a new stake in Spero Therapeutics during the 2nd quarter valued at $100,000. Quadrature Capital Ltd acquired a new position in shares of Spero Therapeutics in the second quarter valued at approximately $90,000. Invesco Ltd. acquired a new stake in Spero Therapeutics during the 2nd quarter worth approximately $43,000. Stonepine Capital Management LLC bought a new stake in Spero Therapeutics in the 2nd quarter valued at $455,000. Finally, Assenagon Asset Management S.A. bought a new stake in Spero Therapeutics in the 3rd quarter valued at $70,000. 25.60% of the stock is owned by institutional investors and hedge funds.

Spero Therapeutics Company Profile

Spero Therapeutics is a clinical‐stage biopharmaceutical company focused on the discovery and development of novel therapies to address multidrug‐resistant bacterial infections. Headquartered in Boston, Massachusetts, the company aims to advance a pipeline of oral and intravenous antibiotic candidates designed to treat serious infectious diseases that pose significant public health challenges.

The company’s lead candidate, tebipenem HBr, is an oral carbapenem antibiotic being developed for the treatment of complicated urinary tract infections caused by resistant Gram‐negative pathogens.